Viridian Therapeutics logo

Viridian Therapeutics

Boulder, CO

Viridian Therapeutics, Inc. operates as a biotechnology company. The Company specializes in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Viridian Therapeutics serves customers in the United States.

viridiantherapeutics.com

Employbl Premium

Get the inside track on Viridian Therapeutics

Premium profiles, AI research on tech stack and hiring, 61,000+ ATS job listings, saved searches, and an AI chat that knows the SF startup scene.

  • AI chat about Viridian Therapeutics's culture, stack, and interview process
  • Save jobs and get alerts on new openings
  • Full premium profiles across our company index
  • 7-day free trial, then $25/mo. Cancel anytime.

Company Details

Founded

2010

Employees

252 employees

Raised

$1,654,697,600

Headquarters Location

Boulder, CO

Public

Yes

Acquired

Yes

CEO

Steve MahoneySteve Mahoney

Founders

William Marshall
William Marshall

Company Collections

These are collections Viridian Therapeutics is a part of. Click on the collection name to view similar companies.

Viridian Therapeutics Headquarters Location

6200 Lookout Rd #100, Boulder, CO, 80301-3695

Loading map…

Total Amount Raised: $1,654,697,600

Viridian Therapeutics Funding Rounds

  • Post Ipo Debt

    $225,000,000

  • Post Ipo Equity

    $125,000,014

  • Post Ipo Equity

    $289,000,000

  • Post Ipo Debt

    $55,000,000

  • Post Ipo Equity

    $225,000,000

  • Post Ipo Equity

    $150,000,000

  • Post Ipo Equity

    $185,000,000

  • Post Ipo Debt

    $75,000,000

  • Post Ipo Equity

    $85,000,000

  • Post Ipo Equity

    $90,997,328

  • Series Unknown

    $27,000,000

  • Seed

    $2,000,000

  • Post Ipo Equity

    $1,500,000

  • Series C

    $40,700,000

  • Series B

    $8,500,000

  • Series B

    $7,000,000

  • IPO

    Unknown

  • Series B

    $20,000,000

  • Convertible Note

    $6,000,000

  • Convertible Note

    $25,000,000

  • Series A

    $4,000,000

  • Series A

    $8,000,000

Funding info provided by Diffbot.

Viridian Therapeutics Reviews

0 out of 5 stars

Based on 0 reviews

Review data

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Viridian Therapeutics.

Recent reviews